229 related articles for article (PubMed ID: 26270474)
1. High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid.
Hendrickson RC; Lee AY; Song Q; Liaw A; Wiener M; Paweletz CP; Seeburger JL; Li J; Meng F; Deyanova EG; Mazur MT; Settlage RE; Zhao X; Southwick K; Du Y; Holder D; Sachs JR; Laterza OF; Dallob A; Chappell DL; Snyder K; Modur V; King E; Joachim C; Bondarenko AY; Shearman M; Soper KA; Smith AD; Potter WZ; Koblan KS; Sachs AB; Yates NA
PLoS One; 2015; 10(8):e0135365. PubMed ID: 26270474
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer's disease: a 24-month follow-up study.
Lim B; Sando SB; Grøntvedt GR; Bråthen G; Diamandis EP
Neurobiol Aging; 2020 Sep; 93():97.e1-97.e7. PubMed ID: 32362369
[TBL] [Abstract][Full Text] [Related]
3. A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease.
Brinkmalm G; Sjödin S; Simonsen AH; Hasselbalch SG; Zetterberg H; Brinkmalm A; Blennow K
Proteomics Clin Appl; 2018 Jan; 12(1):. PubMed ID: 29028155
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease.
Sathe G; Na CH; Renuse S; Madugundu AK; Albert M; Moghekar A; Pandey A
Proteomics Clin Appl; 2019 Jul; 13(4):e1800105. PubMed ID: 30578620
[TBL] [Abstract][Full Text] [Related]
5. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases.
Yin GN; Lee HW; Cho JY; Suk K
Brain Res; 2009 Apr; 1265():158-70. PubMed ID: 19368810
[TBL] [Abstract][Full Text] [Related]
6. An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease.
Hölttä M; Minthon L; Hansson O; Holmén-Larsson J; Pike I; Ward M; Kuhn K; Rüetschi U; Zetterberg H; Blennow K; Gobom J
J Proteome Res; 2015 Feb; 14(2):654-63. PubMed ID: 25490617
[TBL] [Abstract][Full Text] [Related]
7. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects.
Castaño EM; Roher AE; Esh CL; Kokjohn TA; Beach T
Neurol Res; 2006 Mar; 28(2):155-63. PubMed ID: 16551433
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome.
Belbin O; Xiao MF; Xu D; Carmona-Iragui M; Pegueroles J; Benejam B; Videla L; Fernández S; Barroeta I; Nuñez-Llaves R; Montal V; Vilaplana E; Altuna M; Clarimón J; Alcolea D; Blesa R; Lleó A; Worley PF; Fortea J
Mol Neurodegener; 2020 Aug; 15(1):46. PubMed ID: 32807227
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
Spellman DS; Wildsmith KR; Honigberg LA; Tuefferd M; Baker D; Raghavan N; Nairn AC; Croteau P; Schirm M; Allard R; Lamontagne J; Chelsky D; Hoffmann S; Potter WZ; ;
Proteomics Clin Appl; 2015 Aug; 9(7-8):715-31. PubMed ID: 25676562
[TBL] [Abstract][Full Text] [Related]
10. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
[TBL] [Abstract][Full Text] [Related]
13. Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.
Wildsmith KR; Schauer SP; Smith AM; Arnott D; Zhu Y; Haznedar J; Kaur S; Mathews WR; Honigberg LA
Mol Neurodegener; 2014 Jun; 9():22. PubMed ID: 24902845
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
[TBL] [Abstract][Full Text] [Related]
15. Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.
Lleó A; Núñez-Llaves R; Alcolea D; Chiva C; Balateu-Paños D; Colom-Cadena M; Gomez-Giro G; Muñoz L; Querol-Vilaseca M; Pegueroles J; Rami L; Lladó A; Molinuevo JL; Tainta M; Clarimón J; Spires-Jones T; Blesa R; Fortea J; Martínez-Lage P; Sánchez-Valle R; Sabidó E; Bayés À; Belbin O
Mol Cell Proteomics; 2019 Mar; 18(3):546-560. PubMed ID: 30606734
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
18. Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF.
Boiten WA; van Steenoven I; Xiao MF; Worley PF; Noli B; Cocco C; Ferri GL; Lemstra AW; Teunissen CE
Cells; 2020 Dec; 10(1):. PubMed ID: 33383752
[No Abstract] [Full Text] [Related]
19. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Hansson O; Nielsen HM
PLoS One; 2015; 10(8):e0135458. PubMed ID: 26270969
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
